Kenya - İngilizce - Pharmacy and Poisons Board

q pharma dmcc unit no: 2681 dmcc business centre level no - rosuvastatin - tablet - rosuvastatin 5mg - rosuvastatin

Tanzanya - İngilizce - Tanzania Medicinces & Medical Devices Authority

ccl pharmaceuticals private limited, pakistan - cefuroxime sodium 750mg - granules for injection - k750mg/vial

Kenya - İngilizce - Pharmacy and Poisons Board

q pharma dmcc unit no: 2681 dmcc business centre level no. 1 - linagliptin 2.5mg + metformin hcl tablet 500mg - coated tablet - linagliptin 2.5mg + metformin hcl tablet 500mg - metformin and linagliptin

Kenya - İngilizce - Pharmacy and Poisons Board

q pharma dmcc unit no: 2681 dmcc business centre level no. 1 - linagliptin 5mg + metformin hcl 1000mg tablet - tablet - linagliptin 5mg + metformin hcl 1000mg tablet - metformin and linagliptin

Kenya - İngilizce - Pharmacy and Poisons Board

q pharma dmcc unit no: 2681 dmcc business centre level no. 1 - empagaliflozin 25mg + linagliptin 5mg+metformin… - coated tablet - empagaliflozin 25mg + linagliptin 5mg+metformin… - linagliptin

Kenya - İngilizce - Pharmacy and Poisons Board

q pharma dmcc unit no: 2681 dmcc business centre level no. 1 - empagaliflozin 10mg + linagliptin 5mg+metformin… - coated tablet - empagaliflozin 10mg + linagliptin 5mg+metformin… - linagliptin

ABD - İngilizce - NLM (National Library of Medicine)

wilshire pharmaceuticals, inc. - lamotrigine (unii: u3h27498ks) (lamotrigine - unii:u3h27498ks) - lamotrigine 25 mg

ABD - İngilizce - NLM (National Library of Medicine)

wilshire pharmaceuticals, inc. - nitroglycerin (unii: g59m7s0ws3) (nitroglycerin - unii:g59m7s0ws3) - nitroglycerin 400 ug

ABD - İngilizce - NLM (National Library of Medicine)

wilshire pharmaceuticals inc - meclizine hydrochloride (unii: hdp7w44cio) (meclizine - unii:3l5tq84570) - meclizine hydrochloride tablets are indicated for the treatment of vertigo associated with diseases affecting the vestibular system in adults. meclizine hydrochloride tablets are contraindicated in patients with a hypersensitivity to meclizine or any of the inactive ingredients [see adverse reactions (6) and description (11)]. risk summary data from epidemiological studies have not generally indicated a drug-associated risk of major birth defects with meclizine during pregnancy. however, in a published study, an increased incidence of fetal malformations was observed following oral administration of meclizine to pregnant rats during the period of organogenesis, at doses similar to those used clinically. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. the background risk of major birth defects and miscarriage for the indicated population is unknown. data human data epidemiological studies

ABD - İngilizce - NLM (National Library of Medicine)

wilshire pharmaceuticals, inc. - nateglinide (unii: 41x3pwk4o2) (nateglinide - unii:41x3pwk4o2) - nateglinide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. limitations of use : nateglinide tablets should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. nateglinide tablets are contraindicated in patients with a history of hypersensitivity to nateglinide tablets or its inactive ingredients. pregnancy category c there are no adequate and well-controlled studies of nateglinide in pregnant women. it is unknown whether nateglinide tablets can cause fetal harm when administered to a pregnant woman. nateglinide tablets should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. in the rabbit, embryonic development was adversely affected and the incidence of gall bladder agenesis or small gallbladder was increased at a dose of 500 mg/kg (approximately 27 times the human therapeutic exposure of 120 mg three times daily, based on bod